Certified Global Research Member

Key Questions Answered

Global Market Outlook
In-depth analysis of global and regional trends
Analyze and identify the major players in the market, their market share, key developments, etc.
To understand the capability of the major players based on products offered, financials, and strategies.
Identify disrupting products, companies, and trends.
To identify opportunities in the market.
Analyze the key challenges in the market.
Analyze the regional penetration of players, products, and services in the market.
Comparison of major playersâ€™ financial performance.
Evaluate strategies adopted by major players.
Recommendations

Why Choose Market Research Future?

Vigorous research methodologies for specific market.
Knowledge partners across the globe
Large network of partner consultants.
Ever-increasing/ Escalating data base with quarterly monitoring of various markets
Trusted by fortune 500 companies/startups/ universities/organizations
Large database of 5000+ markets reports.
Effective and prompt pre- and post-sales support.

Asia Pacific Gastrointestinal Drugs Companies

Gastrointestinal drugs companies in the Asia-Pacific region focus on developing medications for the treatment of gastrointestinal disorders. These companies contribute to gastroenterology by providing pharmaceutical solutions for conditions such as acid reflux, irritable bowel syndrome (IBS), and inflammatory bowel disease (IBD), enhancing digestive health.

Latest Asia-Pacific Gastrointestinal Drugs Companies Updates:

Dec 2023

Takeda Pharmaceutical Company Limited Launched their Entyvio® (vedolizumab) for the treatment of ulcerative colitis in China, expanding their market reach in the region.Partnered with research institutions in Japan to develop AI-powered tools for early diagnosis and personalized treatment of GI diseases.

Eisai Received regulatory approval for their Halaven® (erituximab) for the treatment of advanced gastric cancer in South Korea, offering a new treatment option for patients.Collaborated with healthcare providers in Southeast Asia to improve access to GI medications and raise awareness about GI health management.

AstraZeneca Presented positive Phase III data on their Nexium® (esomeprazole) for the prevention of esophageal recurrence in Barrett's esophagus patients in China, strengthening their position in the acid reflux management market.Partnered with government agencies in India to implement public health education programs on GI health and disease prevention.

Sanofi S.A. Introduced their Zetia® (ezetimibe) in combination with Zocor® (simvastatin) for the treatment of high cholesterol in Japan, targeting a broader patient population.Focused on expanding their portfolio of GI medications and digital health solutions in the Asia-Pacific region.

Johnson & Johnson Announced the development of a novel oral medication for the treatment of ulcerative colitis, aimed at offering a more convenient and patient-friendly treatment option.Collaborated with startups and technology companies to develop innovative diagnostic tools and digital platforms for personalized GI care.

List of Asia-Pacific Gastrointestinal Drugs Key companies in the market

Abbott,

Allergan Plc,

AstraZeneca,

Eli lilly Company,

Hoffmann-La Roche Ltd,

GlaxoSmithKline plc,

Pfizer Inc,

Valeant Pharmaceuticals

Asia Pacific Gastrointestinal Drugs Companies

Leading companies partner with us for data-driven Insights

Kindly complete the form below to receive a free sample of this Report

Please fill in Business Email for Quick Response

We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.

Purchase Option
	Single User	$ 4,950
	Multiuser License	$ 5,950
	Enterprise User	$ 7,250
Compare Licenses

Tailored for You

Dedicated Research on any specifics segment or region.
Focused Research on specific players in the market.
Custom Report based only on your requirements.
Flexibility to add or subtract any chapter in the study.
Historic data from 2014 and forecasts outlook till 2040.
Flexibility of providing data/insights in formats (PDF, PPT, Excel).
Provide cross segmentation in applicable scenario/markets.